Clinical Trial

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Study acronym: REPROGRAM-02
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-07-15; most recent amendment 2024-12-19.
Status change: Not Yet Recruiting → Recruiting 2023-05-25
Trial Details
NCT Number NCT05462613
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Conditions Metastatic Colorectal Cancer
Enrollment 446 participants
Start Date 2023-05-09
Primary Completion 2029-11 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2024-12-20